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Abstract
Multiple myeloma (MM) is a clonal plasma-cell neoplastic disorder arising from an indolent premalignant disease
known as monoclonal gammopathy of undetermined significance (MGUS). MM is a biologically complex
heterogeneous disease reflected by its variable clinical responses of patients receiving the same treatment.
Therefore, a molecular identification of stage-specific biomarkers will support a more individualized precise
diagnostic/prognostic approach, an effective therapeutic regime, and will assist in the identification of novel
therapeutic molecular targets. The metastatic suppressor/anti-resistance factor Raf-1 kinase inhibitor protein
(RKIP) is poorly expressed in the majority of cancers and is often almost absent in metastatic tumors. RKIP inhibits
the Raf/MEK/ERK1/2 and the NF-κB pathways. Whereby all tumors examined exhibited low levels of RKIP, in
contrast, our recent findings demonstrated that RKIP is overexpressed primarily in its inactive phosphorylated
form in MM cell lines and patient-derived tumor tissues. The underlying mechanism of RKIP overexpression in
MM, in contrast to other tumors, is not known. We examined transcriptomic datasets on Oncomine platform
(Life Technologies) for the co-expression of RKIP and other gene products in both pre-MM and MM. The
transcription of several gene products was found to be either commonly overexpressed (i.e., RKIP, Bcl-2, and DR5)
or underexpressed (i.e., Bcl-6 and TNFR2) in both pre-MM and MM. Noteworthy, a significant inverse correlation
of differentially expressed pro-apoptotic genes was observed in pre-MM: overexpression of Fas and TNF-α and
underexpression of YY1 versus expression of anti-apoptotic genes in MM: overexpression of YY1 and underexpression
of Fas and TNF-α. Based on the analysis on mRNA levels and reported studies on protein levels of the above various
genes, we have constructed various schemes that illustrate the possible cross-talks between RKIP (active/inactive) and
the identified gene products that underlie the mechanism of RKIP overexpression in MM. Clearly, such cross-talks
would need to be experimentally validated in both MM cell lines and patient-derived tumor tissues. If validated, the
differential molecular signatures between pre-MM and MM might lead to a more precise diagnosis/prognosis of the
disease and disease stages and will also identify novel molecular therapeutic targets for pre-MM and MM.
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Background
Multiple Myeloma (MM) is an incurable hematological
malignancy of plasma cells with low proliferation in the
bone marrow. Patients with MM account for 10% of
deaths caused by blood cancers and have a median sur-
vival of approximately 5 years. Uncontrolled growth can
lead to bone marrow failure, which can cause anemia,
thrombocytopenia and leukopenia. In addition, MM has
been associated with renal dysfunction. MM cells inter-
act with nonmalignant cells in the bone marrow micro-
environment, enhancing bone loss and osteoporosis,
causing severe pain. Together, MM biology is complex
and warrants a deeper molecular understanding to sub-
sequently enhance MM therapy [1, 2].
Several mechanisms have been proposed underlying
both the innate and acquired resistance of MM to
various therapies, which include the activation of
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survival/anti-apoptotic pathways, such as the PI3K/
AKT, JAK/STAT3, TGFβ/β-catenin, Wnt, Notch, IGF,
and NF-κB pathways [3–10]. In agreement, we have
previously reported a dysregulated NF-κB/YY1/Snail/
RKIP/PTEN loop detected in many cancers and showed
that it promotes cell survival, proliferation, induces an
epithelial to mesenchymal transition (EMT), potentiates
invasion and metastasis, maintains drug/immune resist-
ance, promotes anti-apoptotic mechanisms, and regulates
the cancer stem cell phenotype [11, 12]. In short, high
RKIP expression inhibits NF-κB, thereby inhibiting Snail,
YY1, AKT while inducing PTEN and pro-apoptotic fac-
tors. Conversely, with low RKIP expression, the opposite
holds true [13–15]. Noteworthy, unlike most tumor cells,
we have previously reported that MM cells overexpress
the inactive phosphorylated form of RKIP and, therefore,
is of consideration in our present study [11]. While several
comprehensive reviews of RKIP have recently been re-
ported [16–20], we specifically investigated the expression
of RKIP/p-RKIP and potential cross-talk pathways of
correlated gene products in both multiple myeloma (MM)
and pre-MM, using a subset of relevant genes in the pub-
licly available Oncomine database.
Differential RKIP expression and activity in cancer
and MM
The human RKIP gene is located on chromosome 12q24
and contains a promoter region with several sequences
involved in the regulation of RKIP transcription, such as
the E1-Box, E2-Box, CpG islands, and androgen-response
elements (ARE) [21–23]. Like many proteins, RKIP can
undergo post-translational phosphorylation modifications,
which alter its conformation-dependent function. Specific-
ally, mediated by its isoenzymes (α,-βI, −βII, −γ, and atyp-
ical ζ) and in response to growth factor stimuli, PKC
phosphorylates RKIP at Ser153, thus inducing a structural,
inactivating change in the RKIP ligand-binding pocket,
causing RKIP to dissociate with Raf-1 and thereby activat-
ing the ERK/MAPK pathways [24–27]. On the other hand,
unphosphorylated RKIP may bind MEK and ERK, causing
Raf-1-MEK dissociation and ERK signaling mitigation.
When observing RKIP activity during the cell cycle of
cultured mammalian cells, hyperactivation of the MAPK
pathway in RKIP-deficient cells displayed decreased
localization of phosphorylated and active Aurora B to
kinetochores, thus indicating RKIP activity in spindle
checkpoint regulation [28, 29]. Indeed, in an RKIP-
dependent manner during G1/S and G2/M transitions,
RKIP influenced cell cycle kinetics as its overexpression
was found to reduce cell growth and proliferation rate,
therefore suggesting a tumor suppressive role for the
endogenous kinase inhibitor [30].
RKIP was reported to inhibit the expressions of both the
Raf/MEK/ERK and the NF-κB signaling pathways through
a physical interaction with B-Raf and an auto-regulatory
feedback loop, respectively [15, 31–33]. RKIP is often re-
ferred to as PEPB1 (phosphatidyl ethanolamine binding
protein 1) as member of the PEBP family of proteins and
is expressed in almost all normal tissues in mammals [34].
However, RKIP expression is reduced in many cancers
and is known to be a tumor metastasis suppressor gene
product, explaining its downregulation during metastasis
[34–40]. RKIP modulates apoptotic pathways, and its
overexpression has been shown to reverse tumor chemo-
and immune-resistance [41, 42]. Furthermore, a dysregu-
lated NF-κB/Snail/YY1/RKIP loop can cause tumor cell
resistance to cytotoxic drugs via inhibition of apoptosis
[41, 42].
RKIP also regulates glycogen synthase kinase 3 (GSK3B)
by both binding and maintaining GSK3β protein levels as
well as inhibiting the activation of GSK3β targets. There-
fore, RKIP indirectly inhibits the cell cycle inducing gene
cyclin-D1 as well as the EMT and invasion inducing genes
β-catenin, Snail and Slug [43]. RKIP also maintains a
subdued oxidative stress response in cells in an unclear
mechanism [30].
Regulation of RKIP expression and its biologic
functions
Snail is a transcriptional repressor of RKIP that binds
to E-box cis-elements in the RKIP promoter and re-
cruits mSin3A histone deacetylases and transcriptional
repressor complexes [44, 45]. In the presence of Snail,
the enhancer of Zeste homolog 2 (EZH2) inhibits RKIP
expression at the transcriptional level, which hastens
cellular invasion. RKIP gene expression can also be
inhibited by microRNAs as the RKIP 3’-UTR contains a
target identified by miR-224 in breast cancer cell lines
[46]. Conversely, the overexpression of miR-let-7, miR-
1, and miR-16 have been shown to mildly enhance
RKIP protein translation, whereas overexpression of
miR-155 has a destabilizing effect on RKIP protein sta-
bility [45, 47, 48].
NF-κB positively regulates both Snail and Yin Yang 1
(YY1), which further inhibit RKIP, which has similarly
been shown to inhibit Snail transcription itself [44, 45,
49]. Indeed, upregulated RKIP was observed to act in a
feedback mechanism by which NF-κB, Snail, and YY1
were inhibited.
As the only known physiological negative regulator of
the MAPK pathway, RKIP is also a key player in cellular
migration through its negative regulation of NF-κB and
its target pro-invasion MMPs [30, 50–53]. Interestingly,
RKIP induction additionally inhibits the EMT-related
genes MAPK, Myc, lin28, let7, vimentin and fibronectin,
while upregulating the epithelial genes E-cadherin and
cytokeratin 18 [45, 49]. Its overexpression can also in-
duce tumor cell sensitivity to TRAIL apoptosis, perhaps
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due to consequential inhibition of YY1 and upregula-
tion of DR5 [54, 55]. Immunologically, active RKIP may
serve as a cancer surveillance gene, since its low ex-
pression in tumor cells allows their immune cytotoxic
effector cell evasion [55].
RKIP Expression in multiple myeloma
Low RKIP expression is found in many cancers, such as
bladder, breast, gastric, non-small cell lung, prostate,
and other cancers [20, 56–58]. In metastatic melanoma,
downregulation of both RKIP and phosphorylated RKIP
has been noted, while low RKIP and high-phosphorylated
RKIP expression may be indicative of non-metastatic
melanoma [59].
For most solid tumors, the majority of studies has
shown that loss of RKIP may be of prognostic significance
with regard to overall survival, disease free survival, and
presence of metastasis [60]. In MM, RKIP expression is
high. RKIP and the inactivated p-Ser153 form of RKIP are
overexpressed in multiple myeloma cell lines and patients’
tissues compared to other tumors, healthy B cells, and
healthy bone marrow. Specifically, about half of the RKIP
positive cells in MM are in the phosphorylated form. This
high RKIP expression in MM is positively correlated with
a more aggressive diagnosis usually resulting in a worse
prognosis. It also correlates with other aggressive prognos-
tic factors, such as IgH translocations, which have been
shown to increase mortality. Thus, it is possible that the
high expression of inactive RKIP in MM may allow for the
constitutive activation of survival pathways and cell
growth and proliferation [11]. The relationship between
the expression of RKIP in MM and the regulatory gene
products in MM was analyzed below.
Correlation Between RKIP Expression in MM and Various
Gene Products Expressed in MM: Criteria for Selection
Bioinformatics analyses were performed via informa-
tion found in the Oncomine Database at https://www.
oncomine.org. A differential screen was selected for
cancer vs. normal tissue, MM being the selected cancer,
and mRNA being the parameter used for the datasets.
The following gene products were analyzed for their rela-
tive associations with the reported activation of RKIP:
AKT, Bcl-2, Bcl-6, CIAP1, DR5, E-cadherin, Fas, FasL,
NF-κB, PTEN, SNAI1, SNAI2, TNF-α, TNFR-1, TNFR-2,
TRAIL, XIAP, and YY1 [11, 13, 14, 41, 54, 61–65]. These
gene products were selected because of their determined
or hypothesized importance in multiple myeloma based
on the reported literature. Three datasets were initially
analyzed, namely, the Agnelli Myeloma 3 (Dataset 1), the
Zhan Myeloma (Dataset 2), and the Zhan Myeloma 3
(Dataset 3). Each dataset used bone marrow plasma cell
tissues for their analyses. Dataset 1 has 133 MM and 5
plasma cell leukemia (PLK) samples with a p-value set
to ≤ 0.05 [66]. Dataset 2 has 74 MM, 37 plasma cell, 7 ton-
sillar lymphomas and 31 healthy samples with a p-value
set to ≤ 0.0001 [67]. Dataset 3 lacked of MM samples,
containing only bone marrow and smoldering myeloma
samples and, thus, was not included in the final analysis
due to this small number of samples [68].
Figure 1 provides an example of the Oncomine log2-
mediated intensity graphs for three gene products
(AKT, Fas, and Bcl-2) that exhibited different expres-
sion states: no significant expression for AKT (Fig. 1a),
significant underexpression for Fas (Fig. 1b), and signifi-
cant overexpression for Bcl-2 (Fig. 1c). For dataset 1 and
for dataset 2, p-values of ≤ 0.05 and ≤ 0.0001, respectively,
were considered as significant according to the respective
publications [66, 67]. The analysis of the various gene
products and their correlations with RKIP were examined
using the same methods used in Fig. 1.
Figure 2a, b represents the various pathways that lead
to the expression of the various gene products under the
conditions that the cancer cells express active RKIP
(Fig. 2a) and inactive RKIP (Fig. 2b). These various path-
ways have been represented in the literature [11, 13, 14,
61, 62, 69, 70].
The Oncomine data were used to examine the
mRNA levels of representative gene products in MM
and whether or not they correlated with the expected
findings summarized in Fig. 2. It must be noted that
due to the heterogeneity of the MM cell population, it
is likely that there exist several subsets expressing vari-
ous forms of RKIP, namely a subset expressing exclusively
RKIP, a subset expressing exclusively pRKIP, a subset ex-
pressing both RKIP and pRKIP, and a subset not express-
ing either form of RKIP. Since the Oncomine analysis and
the represented literature analysis were performed with
the unselected cell populations, the overall findings will
vary according to the levels of RKIP and pRKIP and their
proportions within the populations under analysis.
The following analyses of the Oncomine data of vari-
ous gene products are shown in Table 1.
RKIP
RKIP is downregulated in most cancers, but in MM, there
is high RKIP expression, but it is in its phosphorylated (or
inactive pRKIP form). Phosphorylated RKIP antagonizes
unphosphorylated RKIP in inhibiting survival signals and
promoting apoptosis. Phosphorylation represses the activ-
ity of RKIP as an antisurvival factor. In the bioinformatics
data, RKIP was found to be overexpressed in MM, in
agreement with our reported findings, although it did not
discriminate between active RKIP or pRKIP [11].
AKT
In the bioinformatics data, AKT was not significantly over
or underexpressed.
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NF-κB
NF-κB is a protein complex that may act as an antiapopto-
tic factor in MM cells. NF-κB protects MM cells from
apoptosis both by maintaining mitochondrial stability via
Bcl-2 expression, as well as by attenuating death-
receptor–induced apoptosis via CIAP1 and CIAP2 expres-
sion [71]. The ReIB subunit of NF-κB is found to induce
the expression of anti-apoptotic genes CIAP2, Bcl-XL, and
Bcl-2 to promote cell survival [63]. The NF-κB pathway is
both directly and indirectly implicated in regulating EMT
through the transcription and expression of gene products
that participate in the EMT cascade, such as Snail, the
metastasis-inducer, and E-cadherin suppressor transcrip-
tion factors. Snail represses RKIP which, when actively
expressed, inhibits the Raf-1/MEK/ERk and NF-κB sur-
vival pathways implicated in EMT [13].
Low active RKIP would thus be expected to result in
high NF-κB expression. However, no significant variation
in expression of NF-κB was found in either of the two
datasets of the bioinformatics data we investigated – spe-
cifically in regard to NF-κB1, the nuclear factor of kappa
light polypeptide gene enhancer in B cells (Oncomine).
Fig. 1 Oncomine log2-mediated intensity graphs for three examples. The graphs represented were derived from the Oncomine database and
indicate the expression profiles of three different gene product in MM: a No significant overexpression for AKT; b Significant underexpression of
Fas; c Significant overexpression of Bcl-2
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YY1
NF-κB is a protein complex that regulates the tran-
scription of both Snail and YY1 (Ying Yang 1). YY1
positively regulates Snail and, thus, indirectly re-
presses RKIP. Additionally, there are preliminary find-
ings showing YY1 may directly repress RKIP by
binding to its promoter. In either case, it is known
that upregulated RKIP inhibits NF-κB activation via a
well-documented feedback mechanism, and this, as
expected, results in the inhibition of downstream NF-κB
effectors, namely, Snail and YY1. However, if NF- κB is
phosphorylated, the opposite holds true, at least in part,
due to its inactivity [13].
Specifically, YY1 has been reported to be overex-
pressed in most MM tumor cells [72], which leads to
the expectation that expression of YY1 and pRKIP
would be upregulated in MM [54]. Despite this expect-
ation, the bioinformatics MM data did not show
Fig. 2 a MM Expressing Active RKIP. Blue arrows signify the interactions of gene products. Black arrows signify whether the expression of the
associated gene product is increased or decreased. If RKIP expression is assumed to be high and functional, then high DR5 expression would be
expected through the action of NF-κB inhibiting YY1 [14]. PTEN is expected to be highly expressed through the action of NF-κB inhibiting YY1,
which will no longer inhibit PTEN, thus causing PTEN overexpression [13]. Bcl-2 is overexpressed in the data, but according to findings in literature, if
RKIP is overexpressed, Bcl-2 should be inhibited via NF-κB and PTEN [61, 69]. In the outlined pathway, Fas is expected to be overexpressed, but in the
data, Fas is overexpressed in MM [13]. No clear relationship is determined with RKIP overexpression and Bcl-6, TNFR-2, TRAIL, and TNF-α. b MM
Expressing Inactive, Phosphorylated RKIP. Blue arrows signify the interactions of gene products. Black arrows signify whether the expression of
the associated gene product is increased or decreased. In multiple myeloma, high RKIP expression often corresponds to phosphorylated RKIP,
which is inactive [11]. Inactive (“low” or phosphorylated RKIP) would correspond to TNF-α overexpression via the expression of NF-κB, since
inactive RKIP may not be able to inhibit NF-κB [70]. This would also correspond to underexpression of Fas via NF-κB's activation of YY1, which
would inhibit Fas [13]. The overexpression of Bcl-2 would be explained via the inactivation of PTEN via YY1 expression and the activation of
Bcl-2 with NF-κB [61, 69] However, in the data, PTEN and DR5 are overexpressed and Bcl-6 is underexpressed, which is opposite to their expected
expression found literature findings [13, 62]. There is no clear relationship between RKIP inactivation and TNFR-2 and TRAIL levels
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significant overexpression. Interestingly, however, in
pre-MM, YY1 was significantly underexpressed.
SNAI1
SNAI1, often referred to as Snail, can transcriptionally in-
hibit RKIP [44]. Likewise, RKIP has been shown to inhibit
the transcription of Snail at the mRNA level [45]. Snail
would be expected to be upregulated in MM, considering
pRKIP does not interfere with the dysregulated NF-κB/
YY1/Snail/RKIP/PTEN loop [14]. In the bioinformatics
MM data analyzed, Snail was neither significantly overex-
pressed nor underexpressed in agreement with previous
studies [73].
SNAI2
In the bioinformatics data analyzed, SNAI2, also known as
slug, was not significantly over or underexpressed.
PTEN
PTEN (phosphatase and tensin homolog), which is
inhibited by both YY1 and Snail (which are regulated
by NF-κB), would be expected to be underexpressed
with a dysregulated RKIP loop and low RKIP or high
pRKIP [14]. However, in the bioinformatics data, PTEN
is actually overexpressed in MM in agreement with
high levels of RKIP in a subset of MM cells.
Bcl-2
The Bcl-2 (B-cell lymphoma 2) family of proteins plays
a pivotal role in regulating Cyt C release and apoptosis.
Bcl-2 and Bcl-XL are anti-apoptotic molecules, while,
Bax and Bid are pro-apoptotic. Bcl-2 can block the
release of Cyt C from the mitochondria and prevents
the activation of caspase 3, while Bax and Bid can pro-
mote Cyt C release from the mitochondria and activate
the caspases. Most death modulators act via Bcl-2-
family proteins to regulate Cyt C release [74]. Bcl-2 is
cleaved downstream of caspase activation, which shows
a potential feedback amplification of caspase-induced
mitochondrial dysfunction in IFN-induced apoptosis
[74]. Type I but not type II interferons (IFNs) induce
typical apoptosis through up-regulation of the TRAIL
pathway and modulation of the Bcl-2 family of proteins
in MM [74]. The mitochondria-dependent pathway can
be inhibited by Bcl-2 [75]. Bcl-2 is a target of NF-κB.
NF-κB activation induces the expression of pro-survival
Bcl-2 proteins [61]. Thus, low active RKIP should result
in high NF-κB and high Bcl-2 expression. Bcl-2 has
been reported to be upregulated in MM cells and leads
to chemoresistance for many drugs [76]. In agreement,
the bioinformatics data show significant Bcl-2 overex-
pression for both MM and Pre-MM.
Bcl-6
Bcl-6 (B-cell lymphoma 6) is upregulated in the bone mar-
row microenvironment in multiple myeloma cells [62].
NF-κB mediates TNF-α- induced Bcl-6 expression. Bcl-6
expression is modulated, at least in part, via Janus kinase/
STAT3 and NF-κB pathways [62]. Thus, low active RKIP
or high pRKIP should be expected to result in decreased
Bcl-6 expression due to the mediation of TNF-α- induced
Bcl-6 expression by NF-κB [62]. Activation of CD40 re-
ceptors in B cell lymphoma leads to NF-κB- mediated
IRF4 transcription factor induction, which represses Bcl-6
expression by binding to the Bcl-6 promoter [77]. In the
bioinformatics data, Bcl-6 was found to be underexpressed
in MM, but overexpressed in Pre-MM.
XIAP
RKIP overexpression contributes to the downregulation of
anti-apoptotic gene products, such as XIAP (X-linked
inhibitor of apoptosis protein). Specifically, XIAP is a
target of NF-κB [54]. A dysregulated RKIP would result in
NF-κB expression and, thus, XIAP expression. MM cell
lines usually express high levels of XIAP [78]. In the bio-
informatics data, XIAP had no significant variation.
Table 1 Compilation of bioinformatics MM Gene product
expression data




















Numeral values in table represent absolute significant ratios of
examined datasets
1*(Agnellie Myeloma 3): ≤ 0.05
1 (Zhan Myelona): ≤ 0.0001
1*(Agnellie Myeloma 3): 37 MM; 3 PLK (Agnelli et al. 2009) [66]
1 (Zhan Myelona): 74 MM; 5 MGUS (Zhan et al. 2002) [67]
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CIAP1
RKIP overexpression contributes to the downregulation of
CIAP1 (cellular inhibitor of apoptosis 1), an anti-apoptotic
gene product [54]. The anti-apoptotic gene products
CIAP1 and CIAP2 are recruited to the signaling complex
of TNFR-1 via their interaction with both the TNF-
receptor–associated factor 1 (TRAF1) and TRAF2, exert-
ing an inhibitory effect on caspase-8 activation. There is a
fundamental role for CIAP1/CIAP2 in regulating B-cell
survival and responsiveness, which requires direct binding
to TRAF2. Mutations of TRAF2, TRAF3, and CIAP1/
CIAP2 can contribute to MM [79]. Deletion of CIAP1
plus CIAP2 (but not either alone) leads to uncontrolled
accumulation of primary B cells in vivo [79]. It is also
demonstrated that both CIAP1 and CIAP2 are necessary
for TNF-α-mediated NF-κB activation [80]. Overexpres-
sion of CIAP1 and CIAP2 can cause cells to be highly re-
sistant to TNF-α–induced apoptosis, by blocking the
activation of caspase-8. CIAP1 is regulated by NF-κB,
while CIAP1 and/or CIAP2 also mediate, at least in part,
the protective effect of NF-κB against apoptosis in MM
cells [71]. Thus, a dysregulated RKIP loop would result in
NF-κB expression and thus CIAP1 expression. In the bio-
informatics data, CIAP1 showed no significant variation in
expression.
E-cadherin
Overexpression of RKIP results in the upregulation of
epithelial gene products related to metastasis suppres-
sion, such as E-cadherin [13]. E-cadherin is inhibited
by Snail expression [65]. Overexpression of Snail in
cancer is partly responsible for inducing EMT through
downregulation of E-cadherin [81]. Coupled positive
feedback loops made up of ERK phosphorylating RKIP
and Snail transcriptionally repressing RKIP have a role
in causing a switch-like behavior of E-cadherin expres-
sion. RKIP expression inhibits EMT progression by
preventing E-cadherin suppression [65]. Production of
interleukin-17 (IL-17) in MM cells, leads to repression
and, thus, low expression of E-cadherin [82]. Thus, in
MM, low active RKIP would be expected to result in
low E-cadherin. E-cadherin is negatively regulated by
Snail and since Snail was not overexpressed (see SNAI1
and above SNAI2), it was expected that E-cadherin would
not be overexpressed with high expression of pRKIP. The
bioinformatics data shows no significant variation of the
expression of E-cadherin.
TNF-α, TNFR-1, and TNFR-2
TNF-α is a survival factor for MM cell lines, although it is
less potent than interleukin-6 (IL-6), which is a major
survival factor for malignant plasma cells. TNF-α is pro-
duced in MM cells. TNF-α causes MM cell proliferation
by inducing MM cells into the cell cycle and promotes
long term malignant plasma cell line growth [83]. A
large majority of MM cell lines express the TNF-α
receptor 2, TNFR-2, while a large subset fails to show
TNFR-1 expression [84]. The canonical (classical) path-
way is partly activated through the TNF receptor
family, while the apoptotic extrinsic pathway is medi-
ated by TRAIL. TNFR-1 is the main pro-inflammatory
TNF receptor. In T cells, TNFR-2, but not TNFR-1, is
shown to induce activation of the non-canonical (alter-
native) pathway. Extrinsic apoptosis is induced by the
interaction of the pro-apoptotic ligands: TRAIL, TNF-α
or FasL to their specific receptors on infected or damaged
cells [63]. A large majority of MM cell lines express
TNFR-2, while a large subset fails to show TNFR-1 ex-
pression [84].
TNF-α is secreted into the bone marrow microenviron-
ment by MM cells and induces NF-κB–dependent up-
regulation of adhesion molecules on both MM cells and
bone marrow stromal cells, resulting in increased adhe-
sion. This binding confers resistance to apoptosis and trig-
gers NF-κB–dependent secretion of IL-6. Constitutive
activity of NF-κB in MM cells gets rid of the proapoptotic
effect of TNF-α, due to the up-regulation of CIAP1 and
CIAP2, and induces some proliferation. NF-κB regulates
TNF-α. TNF-α can induce NF-κB nuclear translocation,
CIAP1 and CIAP2 upregulation, and MM cell prolifera-
tion [75]. The TNF-α autocrine-paracrine loop can induce
constitutive activation of NF-κB and YY1 in tumor cells
[63]. Thus, low RKIP should result in the expression of
TNF-α. In the bioinformatics data, TNF-α was overex-
pressed in both Pre-MM and MM. TNFR-2 was underex-
pressed in MM.
Fas and FasL
The system of Fas and Fas ligand (FasL) participates in the
extrinsic apoptotic system. Their levels are increased in
MM and are in parallel with disease stage and may thus
reflect MM progression [85]. FasL plays an important role
in eliminating target cells by effector T lymphocytes
and in suppressing cell immune responses against ma-
lignant and nonmalignant cells. MM cells have been
found to express Fas [86]. FasL has been shown to be
constitutively expressed on the surface of MM cells in a
study by Villunger et al. [87]. However, MM cells are
highly resistant to Fas-mediated apoptosis [88].
Many tumors are resistant to FasL-induced apoptosis.
This was tested in prostate cancer cells. The TNF
autocrine-paracrine loop induces constitutive activation
of transcription factors NF-κB and the transcription re-
pressor YY1 in tumor cells, which both downregulate
Fas and induce resistance to FasL-induced apoptosis
[63]. Fas is transcriptionally regulated by interferons.
Interferon-induced upregulation of Fas has been shown
to sensitize MM cells to Fas-mediated apoptosis. An
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increased basal expression of Fas is associated with a
higher sensitivity to Fas-mediated apoptosis [88]. Fas is
repressed by YY1. Thus, a dysregulated RKIP loop should
result in Fas downregulation [13]. In the MM bioinformat-
ics data, Fas is underexpressed in agreement with the
overexpression of pRKIP, while FasL was overexpressed, in
agreement with the overexpression of RKIP. However, in
the Pre-MM bioinformatics data, Fas is overexpressed.
TRAIL
TRAIL expression has been shown to be significantly
higher in MM cells than plasma cells from MGUS
(monoclonal gammopathy of undetermined signifi-
cance) patients in a study by Kawano et al. [64]. It has
been detected in the myeloma cell cytoplasm. TRAIL
expression in MM cells has been correlated with the
concentration of TRAIL in the bone marrow plasma.
TRAIL expression is positively correlated with osteo-
lytic markers, which suggests that the TRAIL produced
from myeloma cells may have a role in bone resorption
in MM patients [64].
TRAIL plays an important role in NK cell-mediated
immuno- surveillance against tumors. TRAIL was shown
to induce apoptosis in MM cells protected against MM
cell-induced lytic bone destruction in vitro and in a mouse
model [89]. TRAIL has been suggested to have a role in
mediating interferon-α- induced apoptosis [88]. AP-1, a
downstream transcription factors in the MAPK signaling
cascade, acts as one of the key positive transcription fac-
tors for the expression of TRAIL. Upregulation of TRAIL
receptors DR4 and DR5 expression is linked to the activa-
tion of the ERS (endoplasmic reticulum stress) response
in various cancer cell lines. ERS has been found to induce
AP-1 activation and TRAIL expression in macrophages.
TRAIL expression in activated monocytes and macro-
phages may help prevent tumor growth [90].
The NF-κB pathway plays a key role in the regulation of
TRAIL expression in activated human NK cells, indicating
that the proteasome is involved in the regulation of
TRAIL expression through the modulation of NF-κB ac-
tivity. Proteasome inhibition may selectively impair NK
cell cytotoxicity against myeloma cells and other TRAIL-
sensitive tumor cells, possibly resulting in an impairment
of immunosurveillance against such tumors. TRAIL ex-
pression on resting NK cells is undetectable or very low,
but inducible by IL-2 stimulation (NK cells express very
low level of TRAIL). IL-2 significantly induces TRAIL ex-
pression [89]. NF-κB inhibition can increase the sensitivity
of MM cells to TRAIL [71]. Thus, overexpression of RKIP,
which would inhibit NF-κB expression, would be expected
to correlate with uninhibited TRAIL expression, whereas
high pRKIP would be expected to result in low TRAIL
expression. In the bioinformatics data, TRAIL was overex-
pressed in MM.
DR4 and DR5
RKIP overexpression was paralleled with the up-
regulation of DR5 (TRAIL-R2), no change in DR4, and
inhibition of YY1 in the Oncomine data. DR5 is a
proapoptotic receptor, whose expression is mediated
by NF-κB. NF-κB differentially regulates D5. NF-κB can
directly bind to DR5 to activate its expression under cer-
tain conditions. For instance, the anti-apoptotic stimulus
EGF can activate NF-κB and induces its p65 subunit to
bind to the DR5 gene, but fails to increase DR5 expres-
sion, while histone deacetylase 1 (HDAC) inhibitors can
activate NF-κB and p53 to upregulate DR5 expression.
Thus, cooperation with p53 and the NF-κB p65 subunit is
important for DR5 expression [91]. MM cells have been
found to express DR4 or DR5 [86]. High expression and
variable expression of DR4 have been found in MM cell
lines in a study by Mitsiades et al. [92]. DR5 is under the
negative regulation of the transcription factor repressor
YY1, a target of NF-κB [41]. RKIP-induced sensitization to
TRAIL may be due to the inhibition of YY1 and upregula-
tion of DR5. In the presence of inactive RKIP in MM,
DR5 would be expected to be downregulated. RKIP over-
expression may regulate tumor sensitivity to death ligands
by inhibiting YY1 and up-regulating death receptors [41].
In the bioinformatics data, DR5 is overexpressed in MM
in agreement with the overexpression of RKIP.
Conclusions
After reviewing the Oncomine database, the gene rank
and p-value information mined from Oncomine for
each selected gene product with regard to overexpres-
sion and underexpression of the MM case and the Pre-
MM (MGUS) case are shown in Additional file 1: Table
S1. These data were then summarized to depict gene
products that were overexpressed, underexpressed, or
not significantly expressed in either case, and listed in
Tables 1 and 2. Table 1 summarizes the data for the
MM condition and Table 2 summarizes the data for the
Pre-MM condition considering the published significance
values. Gene products with significant overexpression in
MM included Bcl-2, TRAIL, DR5, RKIP, PTEN, and TNF-
α (Table 1). Gene products with significant underexpres-
sion in MM included Bcl-6, Fas, and TNFR-2 (Table 1).
Gene products with significant overexpression in Pre-MM
included Bcl-2, Bcl-6, FasL, and TNF-α (Table 2). YY1 was
found to have significant underexpression in Pre-MM
(Table 2).
Additional files 2 and 3: Tables S2 and S3 summarize
these data for MM and Pre-MM, respectively, with
consideration of less stringent significance values.
These alternative thresholds allowed for the classifica-
tion of significance for several gene products that were
very close to, but not quite at the point of significance,
for the thresholds assumed by the publications. The
Shvartsur et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:62 Page 8 of 14
gene products that were, thus, on the fringe, were con-
sidered. In one comparison, in which the borderline
significant data were considered (data which were very
close to the prescribed significance in the respective
publications), the significance was considered ≤ 0.05 for
Dataset 1 and was ≤ 0.000135 for Dataset 2. The data
were also analyzed with regard to the less stringent sig-
nificance thresholds: a threshold of ≤ 0.05 was consid-
ered for both Dataset 1 and 2; lastly, the threshold was
adjusted to be ≤ 0.05 for both datasets. In addition, the
reports published on the various gene products selected
for this study were reviewed and several figures were
created to summarize this information. Below is a sum-
mary of the specific literature findings regarding each
gene product in question, with the expression expected
from published literature noted along with the expres-
sion found herein the bioinformatics analysis from the
Oncomine database. A comprehensive study has been
reported investigating the role of the NF-κB/Snail/YY1/
RKIP circuitry in multiple myeloma and how each gene
is correlated with the remaining genes in this axis by
examining various myeloma-related Gene Expression
Omnibus (GEO) datasets [73].
As noted previously, Additional file 4: Figure S1 gives a
broad overview of the various interactions of RKIP and its
network of downstream effectors. Figure 3 summarizes
the literature findings of the immediate downstream
targets of RKIP, which are Raf and NF-κB, in addition to
the interaction of TRAIL and its associated downstream
targets [15, 93].
Figure 4 depicts the regulation of Bcl-2 by NF-κB and
PTEN, as well as the process of activation and inactiva-
tion of Bcl-2 [61, 69].
The data mined from Oncomine report the differences
in the expression of gene products between Pre-MM and
MM samples. Many gene products had no significant vari-
ations, especially those in the pre-MM condition, which
may be due to the small pre-MM sample size. Several
gene products did have different expressions in MM and
pre-MM, which may be significant in that these gene
products could play as important factors in the MM pro-
gression. However, a few gene transcripts had modified
expressions in MM as compared to pre-MM. A summary
of the gene products whose expressions were determined
via the bioinformatics data to be significantly overex-
pressed or underexpressed with accordance to published
significance values in MM and Pre-MM is depicted in
Table 3. Gene products’ expressions were also summa-
rized according to the less stringent alternative thresholds
(shown in Additional files 1 and 2: Tables S1 and S2) in
Additional file 5: Table S4.
First, Bcl-6 was found to be overexpressed in Dataset
1 in Pre-MM, but was found to be underexpressed in
Dataset 1 in MM. Bcl-2 was found to be overexpressed
in Dataset 1 in Pre-MM and MM, but was found to be
overexpressed in Dataset 2 in MM, indicating variability
between sample conclusions among datasets. Lastly,
TNF-α was found to be overexpressed in Dataset 1 in
Pre-MM as well as in MM. Bcl-6 is upregulated in the
bone marrow microenvironment in MM cells, while NF-
κB mediates TNF-α- induced Bcl-6 expression. Thus,
Bcl-6 expression is modulated, at least in part, via the
Janus kinase/STAT3 and NF-κB pathways [62].
For certain gene products, a difference in their ex-
pression was noted amongst Pre-MM and MM cases.
For instance, Fas was underexpressed in MM but was
overexpressed in pre-MM. Bcl-6 was underexpressed in
MM but was found to be overexpressed in dataset 1 and
underexpressed in dataset 2 for the pre-MM condition.
Similarly, in MM, TNF-α was overexpressed in dataset 1
but underexpressed in dataset 2, while in pre-MM, TNF-α
was overexpressed. Lastly, in MM, YY1 was overex-
pressed, however, in pre-MM YY1 was underexpressed.
These differences may suggest a correlation between MM
progression and gene product expression in the case of
YY1, Fas, Bcl-6, and TNF-α. Based on Fig. 2b, if RKIP
expression is low, or in the case of MM, if there are high
Table 2 Compilation of Bioinformatics Pre- MM Gene product
expression data




















Numeral values in table represent absolute significant ratios of
examined datasets
1*(Agnellie Myeloma 3): ≤ 0.05
1 (Zhan Myelona): ≤ 0.0001
1*(Agnellie Myeloma 3): 37 MM; 3 PLK (Agnelli et al. 2009) [66]
1 (Zhan Myelona): 74 MM; 5 MGUS (Zhan et al. 2002) [67]
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levels of inactive phosphorylated-RKIP, YY1 levels would
be expected to rise and Fas levels would be expected to
fall, which is only seen in the MM condition.
With regard to RKIP expression, the Oncomine ana-
lyses of the mRNA transcripts in MM did not discrim-
inate between the two subsets of cells that may express
RKIP or phospho-RKIP, which led to the creation of
two possible mechanisms of action of RKIP and its down-
stream effectors in either the active non-phosphorylated
or the inactive, phosphorylated case. It may be possible
that phosphorylated RKIP could have some effect on some
downstream effectors and not on others.
Since RKIP expression regulates both the NF-κB and
MAPK survival pathways, the overexpression of “inactive”
p-Ser153 RKIP in MM might contribute positively to the
overall cell survival/antiapoptotic phenotype and drug
resistance of MM through the constitutive activation of
survival pathways and the downstream transcription of
anti-apoptotic gene products, which can contribute to the
overall cell survival and drug resistance [11, 60]
After analyzing these gene products on Oncomine,
a schematic diagram was developed to attempt to ex-
plain different scenarios for RKIP functioning in MM
and its downstream effectors. Since the RKIP from
the samples was not distinguished from its phosphor-
ylated or non-phosphorylated form, Figs. 2a, b were
created to explore the possibilities that may ensue
from either situation. Figure 2a summarizes the rela-
tionships between high functional RKIP expression
and its corresponding pathways. Figure 2b summa-
rizes the relationship as well as a correlation between
inactive, phosphorylated RKIP, which is found in high
levels in MM, and its potential effects on its downstream
targets. The reported findings in the literature support
some of the Oncomine bioinformatics expression findings
(see above). Several of the gene products analyzed by
Oncomine have expressions that provide support for
Fig. 2a while other gene product expressions provide
support for Fig. 2b. The overexpression of RKIP, DR5,
and PTEN and the underexpression of Bcl-6 in the MM
Fig. 3 RKIP’s Downstream Targets. Red arrows depict the interactions of downstream gene products when RKIP expression is high and black arrows
depict the interactions of downstream gene products when RKIP expression is low. 1: High expression of RKIP inhibits Raf, while low RKIP expression
leads to Raf activation [15]; 2: Low RKIP is correlated with the epithelial to mesenchymal (EMT) transition [15]. Overexpression of Snail can inhibit RKIP
and further induce EMT [81]; 3: RKIP overexpression sensitizes cells to TRAIL-mediated apoptosis [93]; 4: High expression of RKIP leads to inhibition of
NF-κB, while low RKIP expression leads to high expression of NF-κB [15]; 5: TRAIL binds to its receptors, TRAIL-R1 and TRAIL-R2 [94]; 6: Upon binding to
TRAIL-R1 or TRAIL-R2, TRAIL has been shown to stimulate activation of the NF-κB [94]; 7: TNF-α can stimulate TNFR-positive tumor cells [95]. TNF-α
binds to its receptors, TNFR-1 and TNFR-2 [95]; 8: Upon stimulation of TNFR-positive tumor cells by TNF-α, cells can undergo activation of NF-κB [95];
9: TNF-α can induce constitutive activation of NF-κB [63 via NF-kappaB and YY1’, in the regulation of tumor cell resistance to Fas-induced apoptosis];
10: NF-κB mediates TNF-α- induced Bcl-6 expression [62]
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bioinformatics data support the proposed schematic
in Fig. 2a. However, the overexpression of Bcl-2 and
TNF-α and the underexpression of Fas in the MM
bioinformatics data support the proposed schematic
in Fig. 2b.
Future Directions
For prognostic significance, it would be informative to
identify the MM and pre-MM cells for their expression
levels of RKIP and phosphorylated RKIP. Examining the
mRNA transcripts from both MM and pre-MM follow-
ing separation of the cells expressing RKIP or phosphor-
ylated RKIP could help elucidate which downstream
targets are being acted upon or not in each situation. If
these findings are validated, they may provide additional
therapeutic targets for treatment of MM.
Additional files
Additional file 1: Table S1. Summary of Gene Product Overexpression/
Underexpression in MM & Pre MM. (ZIP 294 kb)
Additional file 2: Table S2. Compilation of Bioinformatics MM Gene
Product Expression Data with Various Significance Value Thresholds.
(JPG 158 kb)
Fig. 4 Bcl-2 Regulation. Red arrows depict the interactions of downstream gene products when RKIP expression is high and black arrows depict
the interactions of downstream gene products when RKIP expression is low. 1: Under normal conditions, high RKIP leads to low NF-κB expression,
and thus Bcl-2 expression is low. In cancer cells, low RKIP expresses leads to high NF-κB and thus high Bcl-2 expression [61]; 2: Pten expression
inhibits Bcl-2 [9]; 3: When Bcl-2 is expressed, it may alternatively bind BH3 [96, 97]; 4: Available Bcl-2 can form a bound complex with BH3 [96, 97];
5: When Bcl-2 is bound to BH3, this leads to inactivation of Bcl-2, which has anti-apoptotic activity. Thus, if Bcl-2 is inactivated, apoptosis can occur
[96, 97]; 6: Bcl-2 sequesters tBID (truncated BID) [96, 97]; 7: Bcl-2 can form a complex with tBID [96, 97]; 8: When RKIP expression is high normally,
this leads to downstream activation of Pten, which inhibits AKT. When RKIP expression is low, this leads to low Pten levels, and thus AKT is
expressed [13]; 9: AKT expression leads to BAD inactivation, whereas low AKT allows for available activated BAD [96, 97]; 10: When BAD is in its
activated form, in can react with Bcl-2. Calcineurin B complex activates BAD, which replaces tBID, thus binding Bcl-2 [96, 97]; 11: When BAD binds
Bcl-2, this leads to Bcl-2 activation [96, 97]; 12: The activation of Bcl-2 leads to anti-apoptotic activity. When Bcl-2 is not activated, apoptosis can
occur [96, 97]







Pre- Multiple Myelona (Pre- MM)
Bcl-2 FasL YY1
Bcl-6 TNF-α
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Additional file 3: Table S3. Compilation of Bioinformatics Pre- MM
Gene Product Expression Data with various significance value thresholds.
(JPG 222 kb)
Additional file 4: Figure S1. The RKIP/NF-κB/Snail/YY1/PTEN loop and
its Downstream Targets. Red arrows depict the interactions of
downstream gene products when RKIP expression is high and black
arrows depict the interactions of downstream gene products when RKIP
expression is low. 1: High expression of RKIP leads to inhibition of NF-κB,
while low RKIP expression leads to high expression of NF-κB [15]; 2: Low
levels of NF-κB leads to low CIAP1 and XiAP expression, while high NF-κB
allows for their expression [61]; 3: When CIAP1 and XiAP are expressed,
they inhibit apoptosis, but when their levels are low, apoptosis can
occur [61]; 4: Expression of NF-κB leads to low levels of DR5 [13]; 5:
Low NF-κB expression leads to low expression of YY1 [14]; 6: Low NF-κB
expression leads to low expression of Snail [14]; 7: Low NF-κB leads to
low Bcl-2 expression [61]; 8: Snail represses RKIP normally. Thus, when
Snail expression is low, it allows for RKIP expression [14]; 9: Low levels
of Snail correlate with high expression of Pten [13]; 10: Low levels of
Snail allow for expression of E-cadherin [61]; 11: YY1 is a regulator of
Snail, thus low YY1 expression leads to low Snail expression [13]; 12:
Low levels of YY1 correlate with high expression of Pten [13]; 13: Low
levels of YY1 correlate with the induction of Fas [13]; 14: Low levels of
YY1 correlate with the induction of DR5 [13]; 15: Pten suppresses YY1
via its induction of HIF-2-α transcriptional activity [13]; 16: Pten expression
inhibits Bcl-2 [9]; 17: Pten expression inhibits AKT [13]; 18: AKT
phosphorylates XiAP, preventing it from being degraded. Thus, low
AKT levels would allow for XiAP degradation and thus lead to low
XiAP levels [98]; 19: AKT expression causes inactivation of BAD via
phosphorylation. Thus, low AKT expression does not lead to BAD
phosphorylation and thus is associated with free BAD [96, 97]; 20:
AKT expression leads to BAD inactivation, whereas low AKT allows
for available activated BAD [96, 97]. (JPG 113 kb)
Additional file 5: Table S4. Summary of Gene Product expression in
MM and Pre- MM considering Least Stringent Alternative threshold.
(JPG 113 kb)
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